Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Receivables - Net (2019 - 2025)

Historic Receivables - Net for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $13.1 million.

  • Eton Pharmaceuticals' Receivables - Net rose 13398.32% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.1 million, marking a year-over-year increase of 13398.32%. This contributed to the annual value of $5.4 million for FY2024, which is 5716.8% up from last year.
  • Eton Pharmaceuticals' Receivables - Net amounted to $13.1 million in Q3 2025, which was up 13398.32% from $14.5 million recorded in Q2 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Receivables - Net peaked at $14.5 million during Q2 2025, and registered a low of $300000.0 during Q1 2021.
  • Moreover, its 5-year median value for Receivables - Net was $3.4 million (2023), whereas its average is $4.0 million.
  • As far as peak fluctuations go, Eton Pharmaceuticals' Receivables - Net surged by 1031666.67% in 2021, and later crashed by 6296.0% in 2022.
  • Quarter analysis of 5 years shows Eton Pharmaceuticals' Receivables - Net stood at $5.0 million in 2021, then tumbled by 62.96% to $1.9 million in 2022, then skyrocketed by 84.18% to $3.4 million in 2023, then soared by 57.17% to $5.4 million in 2024, then surged by 144.02% to $13.1 million in 2025.
  • Its Receivables - Net stands at $13.1 million for Q3 2025, versus $14.5 million for Q2 2025 and $4.3 million for Q1 2025.